Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response-Reference-Cited by-同舟云学术

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

Published:2013-07-11 Issue:10 Volume:43 Page:2718-2729
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Hannesdóttir Lára¹,Tymoszuk Piotr¹,Parajuli Nirmala¹,Wasmer Marie-Helene¹,Philipp Sonja¹,Daschil Nina¹,Datta Sebak¹,Koller Johann-Benedikt¹,Tripp Christoph H.²³,Stoitzner Patrizia²,Müller-Holzner Elisabeth⁴,Wiegers Gerrit Jan⁵,Sexl Veronika⁶,Villunger Andreas⁵,Doppler Wolfgang¹

Affiliation:

1. Division of Medical Biochemistry; Biocenter, Innsbruck Medical University; Innsbruck Austria

2. Department of Dermatology; Innsbruck Medical University; Innsbruck Austria

3. Oncotyrol - Center for Personalized Cancer Medicine; Innsbruck Austria

4. Department of Obstetrics and Gynecology; Innsbruck Medical University; Innsbruck Austria

5. Division of Developmental Immunology, Biocenter; Innsbruck Medical University; Innsbruck Austria

6. Institute of Pharmacology and Toxicology; Veterinary University Vienna; Vienna Austria

Funder

Integrated Center for Research and Therapy (IFTZ) of Innsbruck Medical University

Austrian Science Fund FWF and Austrian Cancer Society/Tirol

Austrian Science Fund

Austrian National Bank

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/eji.201242505/fullpdf

Reference41 articles.

1. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors;Mattarollo;Cancer Res.,2011

2. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy;Stagg;Proc. Natl. Acad. Sci. USA,2011

3. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies;Ozao-Choy;Cancer Res.,2009

4. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery;Milano;PLoS ONE,2010

5. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice;Abe;Int. Immunopharmacol.,2010

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pan-cancer analysis of T-cell proliferation regulatory genes as potential immunotherapeutic targets;Aging;2024-06-29

2. Identification of N7-methylguanosine-related miRNAs as potential biomarkers for prognosis and drug response in breast cancer;Heliyon;2024-04

3. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer;Nature Communications;2024-03-20

4. Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: An additional anti-tumor effect of the drug;Biomedicine & Pharmacotherapy;2024-01

5. Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma;2024